drug development

Dana-Farber’s 4-year legal battle shines a light on the origins of PD-1 research — forcing a reckoning on who pioneered the landmark cancer breakthrough
Dana-Farber’s 4-year legal battle shines a light on the origins of PD-1 research — forcing a reckoning on who pioneered the landmark cancer breakthrough
Endpoints
Dana-Farber
drug development
PD-1 inhibitors
Flag link:
Are Phages the Wave of the Future? Using Viruses to Treat Bacterial Diseases
Are Phages the Wave of the Future? Using Viruses to Treat Bacterial Diseases
BioSpace
phages
bacteriophage
drug development
Flag link:
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Flag link:
Pfizer selects first GPCR candidate from Sosei Heptares tie-up
Pfizer selects first GPCR candidate from Sosei Heptares tie-up
Pharmaforum
Pfizer
Sosei Heptares
drug development
R&D
GPCRs
Flag link:
A new study sparks a war of words over the drug industry’s commitment to research
A new study sparks a war of words over the drug industry’s commitment to research
Stat
R&D
drug development
Flag link:
Bicycle Therapeutics Updates Filing for $80 Million IPO
Bicycle Therapeutics Updates Filing for $80 Million IPO
CP Wire
Bicycle Therapeutics
IPOs
drug development
Flag link:
Spectrum bags cancer drugs, interferon platform from ImmunGene
Spectrum bags cancer drugs, interferon platform from ImmunGene
Fierce Biotech
Spectrum Pharmaceuticals
ImmunGene
drug development
interferon
Flag link:
Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases
Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases
Marketwatch
Gilead Sciences
Goldfinch Bio
drug development
kidney disease
Flag link:
Artificial Intelligence is Ramping up in Drug Development
Artificial Intelligence is Ramping up in Drug Development
BioSpace
AstraZeneca
drug development
artificial intelligence
BenevolentAI
Flag link:
Old Evaluation Systems Are Inadequate For AI Health Care And Drug Development Ecosystem
Old Evaluation Systems Are Inadequate For AI Health Care And Drug Development Ecosystem
Forbes
artificial intelligence
R&D
drug development
Flag link:
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
NPR
Alzheimer's disease
R&D
drug development
beta amyloid
Biogen
Eisai
aducanumab
Flag link:
AstraZeneca ups oncolytic virus activity with Transgene deal
AstraZeneca ups oncolytic virus activity with Transgene deal
Fierce Biotech
AstraZeneca
Transgene
oncolytic viruses
drug development
Flag link:
Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge
Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge
Stat
antibiotics
antibiotic resistance
R&D
drug development
Flag link:
Caris aims to bridge gap between patients, precision trials with Pharmatech takeout
Caris aims to bridge gap between patients, precision trials with Pharmatech takeout
BioCentury
Caris
Pharmatech
molecular profiling
drug development
precision medicine
clinical trials
cancer
Flag link:
Reports: Odds of Getting Drugs to Market Range from 6% to 40%
Reports: Odds of Getting Drugs to Market Range from 6% to 40%
BioSpace
R&D
drug development
Flag link:
Biogen says it will not give up on Alzheimer’s after failed trials
Biogen says it will not give up on Alzheimer’s after failed trials
Marketwatch
Biogen
drug development
Alzheimer's disease
Flag link:
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs
Flag link:
A decade of incentives to promote antibiotic development and still no viable route to commercial success
A decade of incentives to promote antibiotic development and still no viable route to commercial success
BioWorld
Achaogen
Zemdri
R&D
drug development
antibiotics
Flag link:
Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics
Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics
Xconomy
antibiotics
drug development
Forge Therapeutics
Basilea
Flag link:
The biotech era in late-stage drug R&D and marketing has arrived. And it looks like it’s here to stay
The biotech era in late-stage drug R&D and marketing has arrived. And it looks like it’s here to stay
Endpoints
R&D
biotech
startups
drug development
Flag link:

Pages